Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

    Journal Title:  Leukemia Primary Author:  Platzbecker U Author(s):  Platzbeck...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Lenalidomide

    ... Lenalidomide is a capsule that is taken by mouth. It is approved for ... with a broader range of MDS patients. For some MDS patients, lenalidomide can improve anemia and reduce or eliminate the need for ...

    Drug last updated 03/24/2016 - 12:32pm.

  3. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... isolated del(5q). METHODS: Patients received lenalidomide 10 mg/day (days 1-21; n = 47) or 5 mg/day (days 1-28; ... cycles, or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?

    ... et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or ... outcomes in these patients are needed. Azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. How we treat lower risk myelodysplastic syndromes.

    ... while anemia of low risk MDS with del 5q responds to Lenalidomide in two thirds of the cases, but this drug should be used ... results have been reported with hypomethylating agents and lenalidomide. Selected patients respond to antithymocyte globulins, while ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Established and novel agents for myelodysplastic syndromes

    ... abnormality or those who fail these initial approaches, lenalidomide may be tried, as can experimental agents. Lower-risk patients ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... the US Food and Drug Administration for its treatment: lenalidomide , 5- azacitidine , and decitabine . These ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. More is better: Combination therapies for myelodysplastic syndromes

    ... are currently three FDA-approved medications for MDS; lenalidomide , azacitidine , and decitabine . The role of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... therapies, such as azacitidine or lenalidomide . The recombinant human erythropoietin (rHuEPO) ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Recent developments in myelodysplastic syndromes

    ... of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald a new era in the ...

    Research Article last updated 07/20/2018 - 5:15pm.